What is Denali Therapeutics Inc.'s convertible preferred stock outstanding shares?

Denali Therapeutics Inc. (DNLI) reported convertible preferred stock outstanding shares of 0 in Q1 2026.

Denali Therapeutics Inc. DNLI Convertible Preferred Stock Outstanding Shares

Convertible Preferred Stock Outstanding Shares at other companies

BridgeBio PharmaBBIO

——

ALN

Alnylam PharmaceuticalsALNY

——

BioCryst PharmaceuticalsBCRX

——

Neurocrine BiosciencesNBIX

——

Praxis Precision Medicines, Inc.PRAX

——

Other financials

Income statement

See full

Revenue-—

Operating income-$137.4M+5.6%

Net income-$128.4M+3.4%

EPS (diluted)-$0.69+11.5%

Balance sheet

See full

Cash & equivalents$390.7M+551%

Total debt$40.0M-22.3%

Total equity$926.1M-17.5%

Total assets$1.3B-0.4%

Cash flow

See full

Operating cash flow-$131.2M+0.2%

CapEx$2.5M-51.4%

Free cash flow-$133.7M+2.1%

Valuation

See full

Market cap$3.93B+54.2%

Profitability

See full

Operating margin-37,938%-37,986pp

Net margin-33,121.9%-33,159pp

FCF margin-31,736.3%-31,830pp

Returns & leverage

See full

Return on equity-49.6%+34.2pp

Debt / equity0×0.0×

Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesOutstanding.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Denali Therapeutics Inc.'s convertible preferred stock outstanding shares?: Denali Therapeutics Inc. (DNLI) reported convertible preferred stock outstanding shares of 0 in Q1 2026.